Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors

被引:53
作者
Coban, C
Ishii, KJ
Gursel, M
Klinman, DM
Kumar, N
机构
[1] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Johns Hopkins Malaria Res Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
[2] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA
关键词
Plasmodium falciparum; oligonucleotides; dendritic cells;
D O I
10.1189/jlb.1104627
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
DNA vaccines, in general, have been found to be poorly immunogenic in nonhuman primates and humans as compared with mice. As the immunogenicity of DNA plasmids relies, to a large extent, on the presence of CpG motifs as built in adjuvants, we addressed the issue of poor immunogenicity by inserting recently identified CpG oligonucleotides (ODN) optimal for human (K-type or D-type CpG ODN) into the backbone of plasmid VR1020. We found that plasmid DNA containing K-type CpG motifs or D-type CpG motifs significantly enhanced the up-regulation of surface molecules and production of interleukin-6 from human peripheral blood mononuclear cells (PBMC) and stimulated monocytes to develop into functionally mature dendritic cells (DC) compared with unmodified plasmid. Monocyte maturation into DC was through plasmacytoid DC present in the culture. It is interesting that the K-type CpG motif-modified plasmid stimulated significant levels of interferon (IFN)-gamma and IFN-alpha from human PBMC. Immunization of mice with D-type CpG motif-modified plasmid, encoding Plasmodium falciparum surface protein 25, yielded enhanced antigen-specific antibodies. Taken together, these results suggest that insertion of immunomodulatory human CpG motifs into plasmid DNA can improve immunogenicity of DNA vaccines.
引用
收藏
页码:647 / 655
页数:9
相关论文
共 36 条
[1]   TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine [J].
Babiuk, S ;
Mookherjee, N ;
Pontarollo, R ;
Griebel, P ;
Littel-Van den Hurk, SV ;
Hecker, R ;
Babiuk, L .
IMMUNOLOGY, 2004, 113 (01) :114-120
[2]   Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients [J].
Calarota, S ;
Bratt, G ;
Nordlund, S ;
Hinkula, J ;
Leandersson, AC ;
Sandström, E ;
Wahren, B .
LANCET, 1998, 351 (9112) :1320-1325
[3]   Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen [J].
Coban, C ;
Ishii, KJ ;
Stowers, AW ;
Keister, DB ;
Klinman, DM ;
Kumar, N .
INFECTION AND IMMUNITY, 2004, 72 (01) :584-588
[4]   Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations [J].
Coban, C ;
Philipp, MT ;
Purcell, JE ;
Keister, DB ;
Okulate, M ;
Martin, DS ;
Kumar, N .
INFECTION AND IMMUNITY, 2004, 72 (01) :253-259
[5]   Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes [J].
Epstein, JE ;
Gorak, EJ ;
Charoenvit, Y ;
Wang, RB ;
Freydberg, N ;
Osinowo, O ;
Richie, TL ;
Stoltz, EL ;
Trespalacios, F ;
Nerges, J ;
Ng, J ;
Fallarme-Majam, V ;
Abot, E ;
Goh, L ;
Parker, S ;
Kumar, S ;
Hedstrom, RC ;
Norman, J ;
Stout, R ;
Hoffman, SL .
HUMAN GENE THERAPY, 2002, 13 (13) :1551-1560
[6]  
Gürsel M, 2002, J LEUKOCYTE BIOL, V71, P813
[7]  
Gursel M, 2002, EUR J IMMUNOL, V32, P2617, DOI 10.1002/1521-4141(200209)32:9<2617::AID-IMMU2617>3.0.CO
[8]  
2-F
[9]   Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major [J].
Gurunathan, S ;
Sacks, DL ;
Brown, DR ;
Reiner, SL ;
Charest, H ;
Glaichenhaus, N ;
Seder, RA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (07) :1137-1147
[10]   A Toll-like receptor recognizes bacterial DNA [J].
Hemmi, H ;
Takeuchi, O ;
Kawai, T ;
Kaisho, T ;
Sato, S ;
Sanjo, H ;
Matsumoto, M ;
Hoshino, K ;
Wagner, H ;
Takeda, K ;
Akira, S .
NATURE, 2000, 408 (6813) :740-745